Akili Interactive Labs
The company plans to use the new funds to expand its therapeutics beyond ADHD.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.
The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.
Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.
Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.
At CES 2019, the digital therapeutic company's CEO and cofounder described work on an independent prescription, procurement and support platform specific to digital medicines.
The study's 19 young participants stuck to their regimens, and along with their parents said that they would be open to continuing treatment sessions.
Also: Greenway Health appoints new CISO; DocuTAP hires SVP of product, EVP of people and culture.
The new digital therapeutic is being developed at a UCSF, and will join Akili Interactive Labs' pipeline of other video game-based therapeutics.